Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid

This publication has 23 references indexed in Scilit:

• A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years
  Molecular Genetics and Metabolism, 2007
• Penetration, diffusion, and uptake of recombinant human α-l-iduronidase after intraventricular injection into the rat brain
  Molecular Genetics and Metabolism, 2005
• Pharmacokinetic profile of recombinant human N‐acetylgalactosamine 4‐sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): a phase I/II study
  Acta Paediatrica, 2005
• Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I
  Molecular Genetics and Metabolism, 2004
• Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome
  New England Journal of Medicine, 2004
• Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)
  The Journal of Pediatrics, 2004
• Intracranial Injection of Recombinant Adeno-associated Virus Improves Cognitive Function in a Murine Model of Mucopolysaccharidosis Type VII
  Molecular Therapy, 2001
• Long‐term outcome of Hurler syndrome following bone marrow transplantation
  American Journal of Medical Genetics, 1993
• Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's Disease
  New England Journal of Medicine, 1991
• REVERSAL OF CLINICAL FEATURES OF HURLER'S DISEASE AND BIOCHEMICAL IMPROVEMENT AFTER TREATMENT BY BONE-MARROW TRANSPLANTATION
  The Lancet, 1981